SCHEMBL2284333

SCHEMBL2284333

C#CCN1CCC(N(C)C)CC1

nearest known ligand 0.47

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.47
MAOB P27338 18/20 0.41
MAOA P21397 5/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25362164 0.80 NPY1R (0.35) BCHE
SCHEMBL25431859 0.80 NPY1R (0.35) BCHE
SCHEMBL7282316 0.79 L3MBTL3 (0.38) BCHE
SCHEMBL1308650 0.79 HRH3 (0.37) BCHE
SCHEMBL31275530 0.78 BCHE (0.36) BCHEMAOBMAOA
SCHEMBL26924070 0.78 BCHE (0.55) BCHEMAOBMAOA
SCHEMBL14979149 0.78 LMNA (0.34) BCHE
SCHEMBL82217 0.76 MAOB (0.45) BCHEMAOBMAOA
SCHEMBL12376563 0.73 CHRM2 (0.41)
SCHEMBL12376552 0.73 HTT (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003662-B2 Heterobicyclic thiophene compounds and methods of use ARRAY BIOPHARMA, INC. (US) 2011-08-23 US disclosed
CN-101522687-A Heterobicyclic thiophene compounds and methods of use ARRAY BIOPHARMA INC (US) 2009-09-02 CN disclosed
EP-1989211-A2 HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER Array Biopharma, Inc. (US) 2008-11-12 EP disclosed
WO-2008063202-A2 HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER ARRAY BIOPHARMA INC. (US) 2008-05-29 WO disclosed
US-20070197537-A1 Heterobicyclic thiophene compounds and methods of use ARRAY BIOPHARMA, INC. 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197537-A1 Heterobicyclic thiophene compounds and methods of use ERBB2, LCK, SRC BCHE 3183/4885MAOB 1178/4885MAOA 2170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.